Lay summary
mRNA vaccines have forever changed our approach to fighting infectious diseases like SARS-CoV-2. As more information becomes available on how they work in the body once administered, it has become apparent that their protective capacity typically diminishes within a few months. It is thought this phenomenon is caused by a decrease in the number of antibodies specifically targeting the pathogen. Here, we aim to vastly improve the antibody responses by creating a new approach to vaccination in which the protein components in the vaccine span the target cell surface to self-modulate immune cell signaling pathways. We are targeting a special subset of immune cells known to enhance antibody responses. With an initial focus on the SARS-CoV-2 vaccines, we aim to reduce the number of booster shots required for protection, thereby enhancing vaccine accessibility and effectiveness.